To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine
Initiator Pharma A/S, a clinical-stage biotech company, today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented candidate drug IP2015, which is in clinical development in erectile dysfunction and neuropathic pain.
Initiator Pharma A/S – Resolutions of the annual general meeting 2023
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 26 May 2023 at 10.00 AM CEST.
INITIATOR PHARMA: Q1 2023 REPORT
Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…
Annual report and Remuneration report 2022 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2022 and Remuneration Report 2022 has now been published and is available on the company´s home page.
Initiator Pharma completes dosing in Phase 2a trial with IP2018
Initiator Pharma A/S, a clinical-stage biotech company, today announced that it has completed dosing all 24 patients for its Phase 2a clinical trial with IP2018. Draft results are expected end of Q2 2023, as previously communicated.
Initiator Pharma has decided not to exercise the option for an undisclosed pain asset
Initiator Pharma A/S, a clinical-stage pharma company, announced today its decision not to exercise the exclusive option agreement for a Phase II/III ready pharmaceutical asset. With this decision the company reiterates previous statement that its current cash position will be sufficient to fund all planned and committed activities through 2024.
Initiator Pharma: Financial calendar for 2023
Initiator Pharma A/S (“Initiator” or the “Company”) announces that the board of directors expects to publish financial reports according to the following schedule:
Initiator Pharma ready to start Phase I pharmacokinetics study for new IP2015 formulations
Initiator Pharma A/S, a clinical-stage pharma company, announced today that it will initiate a Phase I pharmacokinetic study in healthy subects evaluating new oral solid dosage forms enabling a bridging between previous data sets into new future clinical studies for IP2015.